---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-284303"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:13:30.028696+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Neumora receives FDA IND clearance for NMRA-266; starts Phase 1

## Summary
- NMRA-266 is a positive allosteric modulator of M4 muscarinic receptor, licensed from Vanderbilt University.
- Phase 1 SAD/MAD study initiated in healthy adults after FDA IND clearance on Nov 27, 2023.
- First clinical trial for NMRA-266; aims to evaluate safety, tolerability, and pharmacokinetics.
- Neumora focuses on neuroscience; NMRA-266 could treat schizophrenia and other CNS disorders.

## SEC filing metadata
- accession: 0001193125-23-284303
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312523284303/0001193125-23-284303-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312523284303/d614921d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-284303
- JSON: https://secwatch.observer/filing/0001193125-23-284303.json
- Plain text: https://secwatch.observer/filing/0001193125-23-284303.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.